

## **Living with HIV: Understanding the Patient Experience and Appreciating the Science – Plot-Your-Own-Course Activity #2**

### **References**

ACC. ASCVD risk estimator plus. Accessed April 8, 2022. <https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/>

CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) [prescribing information]. ViiV Healthcare. Approved 2021. Revised March 2022. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/212888s005s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf)

CDC. NCHHSTP AtlasPlus. Updated October 1, 2021. Accessed March 3, 2022. <https://www.cdc.gov/nchhstp/atlas/index.htm>

Centers for Disease Control and Prevention. A guide to taking a sexual history. Updated January 14, 2022. Accessed February 4, 2022. <https://www.cdc.gov/std/treatment/SexualHistory.pdf>

Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. *AIDS*. 2019;33(4):701-708. doi:10.1097/QAD.0000000000002111

Ford N, Shubber Z, Hill A, et al. Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. *PLoS One*. 2013;8(11):e79981. doi:10.1371/journal.pone.0079981

Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. *The Lancet HIV*. 2016;3(4):e158-e165. doi:10.1016/s2352-3018(16)00024-2

Giacomelli A, Conti F, Pezzati L, et al. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. *BMC Infect Dis*. 2021;21(1):595. doi:10.1186/s12879-021-06304-3

Gupta S, Sims J, Brinson C, et al. Lenacapavir as part of a combination regimen in treatment naïve PWH: week 54 results. Abstract 138. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/lenacapavir-as-part-of-a-combination-regimen-in-treatment-naive-pwh-week-54-results/>

HIV.gov. Drug database: islatravir. Updated January 13, 2022. Accessed March 28, 2022. <https://clinicalinfo.hiv.gov/en/drugs/islatravir/patient>

Knechten H, Stephan C, Waizmann M, et al. Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort. Abstract P053. Presented at: HIV Glasgow; October 23-26 2020; Virtual. <https://www.hivglasgow.org/wp-content/uploads/2020/11/P053-van-Welzen.pdf>

Llibre JM, Brites C, Cheng CY, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial. Clin Infect Dis. 2022;doi:10.1093/cid/ciac130

Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839-849. doi:10.1016/S0140-6736(17)33095-7

Orkin C. New antiretrovirals and the future of HIV treatment and prevention. Abstract 116. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/new-antiretrovirals-and-the-future-of-hiv-treatment-and-prevention/>

Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124-1135. doi:10.1056/NEJMoa1909512

Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir + rilpivirine every 2 months: ATLAS-2M week 152 results. Poster H03. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/long-acting-cabotegravir-rilpivirine-every-2-months-atlas-2m-week-152-results/>

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated January 20, 2022. Accessed February 4, 2022. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>

Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine. 2016;14(1)doi:10.1186/s12916-016-0588-4

Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379-1389. doi:10.1093/cid/ciz999

Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021;73(2):e485-e493. doi:10.1093/cid/ciaa988

Segal-Maurer S, DeJesus E, Stellbrink H-J, et al. Capsid inhibition with lenacapavir in multidrug-resistant hiv-1 infection. N Engl J Med. 2022;386(19):1793-1803. doi:10.1056/NEJMoa2115542

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112-1123. doi:10.1056/NEJMoa1904398

Swindells S, Lutz T, Van Zyl L, et al. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. *AIDS*. 2022;36(2):185-194. doi:10.1097/QAD.0000000000003025

Triant VA, Perez J, Regan S, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. *Circulation*. 2018;137(21):2203-2214. doi:10.1161/circulationaha.117.028975

Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. *Antivir Ther*. 2017;22(4):295-305. doi:10.3851/IMP3166

Wang R, George N, Ait-Khaled M, et al. Efficacy of tenofovir-lamivudine-dolutegravir for initial and first-line switch ART. Poster 0488. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/low-level-hiv-replication-for-dtg-3tc-vs-taf-based-regimen-in-tango-through-week-144/>